These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22872740)

  • 21. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
    Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
    Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model.
    Gupta P; Jiang ZK; Yang B; Manzuk L; Rosfjord E; Yao J; Lemon L; Noorbehesht K; David J; Puthenveetil S; Casavant JM; Muszynska E; Li F; Leal M; Sapra P; Giddabasappa A
    MAbs; 2021; 13(1):1958662. PubMed ID: 34347577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase
    Ponte JF; Lanieri L; Khera E; Laleau R; Ab O; Espelin C; Kohli N; Matin B; Setiady Y; Miller ML; Keating TA; Chari R; Pinkas J; Gregory R; Thurber GM
    Mol Cancer Ther; 2021 Jan; 20(1):203-212. PubMed ID: 33177153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
    Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
    Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
    van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
    J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species.
    Yip V; Saad OM; Leipold D; Li C; Kamath A; Shen BQ
    Xenobiotica; 2024 Aug; 54(8):511-520. PubMed ID: 38647387
    [No Abstract]   [Full Text] [Related]  

  • 28. Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.
    Vilhelmsson-Timmermand O; Santos E; Thorek DL; Evans-Axelsson S; Bjartell A; Lilja H; Larson SM; Strand SE; Tran TA; Ulmert D
    Nucl Med Biol; 2015 Apr; 42(4):375-80. PubMed ID: 25577038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacologic basis for antibody-auristatin conjugate activity.
    Alley SC; Zhang X; Okeley NM; Anderson M; Law CL; Senter PD; Benjamin DR
    J Pharmacol Exp Ther; 2009 Sep; 330(3):932-8. PubMed ID: 19498104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
    Lamberts LE; Menke-van der Houven van Oordt CW; ter Weele EJ; Bensch F; Smeenk MM; Voortman J; Hoekstra OS; Williams SP; Fine BM; Maslyar D; de Jong JR; Gietema JA; Schröder CP; Bongaerts AH; Lub-de Hooge MN; Verheul HM; Sanabria Bohorquez SM; Glaudemans AW; de Vries EG
    Clin Cancer Res; 2016 Apr; 22(7):1642-52. PubMed ID: 26589435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Fujiwara K; Tsuji AB; Sudo H; Sugyo A; Akiba H; Iwanari H; Kusano-Arai O; Tsumoto K; Momose T; Hamakubo T; Higashi T
    Ann Nucl Med; 2020 Jan; 34(1):13-23. PubMed ID: 31605356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase 1 and Biodistribution Study of ABT-806i, an
    Gan HK; Burge M; Solomon B; Lee ST; Holen KD; Zhang Y; Ciprotti M; Lee FT; Munasinghe W; Fischer J; Ansell P; Fox G; Xiong H; Reilly EB; Humerickhouse R; Scott AM
    J Nucl Med; 2021 Jun; 62(6):787-794. PubMed ID: 33509972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.